Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 48

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 48
---
 of patient care, without requiring substantially new clinical workflows or large capital investments. We are also developing
TAEUS for possible incorporation into new medical equipment manufactured by original equipment manufacturers (“OEMs”), such
as GE Healthcare and others, to enhance the utility of those OEM systems, as described more fully in our Annual Report on Form 10-K. Based
on our design work and our understanding of the medical capital equipment market, we intend to price our initial liver TAEUS system at
a price point of approximately $65,000, which we believe could enable clinical purchasers to recoup their investment in less than one
year by performing a relatively small number of additional procedures, initially paid out-of-pocket by patients until government and private
insurance reimbursement is secured for the TAEUS liver procedures.

Corporate Information

We were incorporated in Delaware in July 2007.
Our corporate headquarters is located at 3600 Green Court, Suite 350, Ann Arbor, Michigan 48105-1570. Our website can be accessed at www.endrainc.com.
The telephone number of our principal executive office is (734) 335-0468. The information contained on, or that may be obtained from,
our website is not, and shall not be deemed to be, a part of this prospectus.

<div align='center'>6

RISK FACTORS</div>

Investing in our securities involves a high degree
of risk. You should carefully consider the risk factors described in our Annual Report on Form 10-K for our most recent fiscal year (together
with any material changes thereto contained in subsequent filed Quarterly Reports on Form 10-Q) and those contained in our other filings
with the SEC, which are incorporated by reference in this prospectus and any accompanying prospectus supplement.

The prospectus supplement applicable to each type
or series of securities we offer may contain a discussion of risks applicable to the particular types of securities that we are offering
under that prospectus supplement. Prior to making a decision about investing in our securities, you should carefully consider the specific
factors discussed under the caption “Risk Factors” in the applicable prospectus supplement, together with all of the other
information contained in the prospectus supplement or appearing or incorporated by reference in this prospectus. These risks could materially
affect our business, results of operations or financial condition and cause the value of our securities to decline. You could lose all
or part of your investment.

<div align='center'>7

USE OF PROCEED